Max Healthcare Institute Limited (MAXHEALTH) is one of India’s largest integrated healthcare providers, formed through the 2020 amalgamation of the erstwhile Max Healthcare with Radiant Life Care, the KKR-backed hospital operator promoted by Abhay Soi. The combined entity listed on the NSE and BSE in August 2020 and today ranks as India’s largest hospital chain by market capitalisation and the second-largest by revenue and EBITDA, behind only Apollo Hospitals.

The network spans 21 healthcare facilities with 6,100+ operational beds, 30+ medical specialities and 6,200+ clinicians, concentrated in Delhi-NCR (its home market and largest cluster) with additional presence in Mumbai (Nanavati-Max, post-merger), Mohali, Bathinda, Dehradun, Nagpur, Lucknow and, most recently, Bhubaneswar via the Kalinga Hospital acquisition. Roughly 85% of bed capacity sits in Metro and Tier-1 cities, underpinning premium case mix and among the highest Average Revenue Per Occupied Bed (ARPOB) in the Indian hospital industry (₹80,000+ per day).

Beyond hospitals, the company operates two smaller but scalable adjacent businesses: Max@Home (homecare — nursing, physiotherapy and diagnostics at home) and Max Lab (standalone pathology/diagnostics outside the hospital network). Flagship centres of excellence include cardiac sciences, oncology, neurosciences, orthopaedics, and complex organ transplants (liver, kidney, heart, lung, bone marrow) — high-acuity specialities that support premium pricing and payor mix skewed toward cash-pay and international patients relative to government scheme business.

Max Healthcare is promoted and led by Abhay Soi as Chairman & Managing Director, who holds 23.71% of the company as sole promoter (KKR, the erstwhile co-promoter, fully exited between 2021-22). The company has pursued an aggressive combination of brownfield bed additions at existing campuses, greenfield “built-to-suit” asset-light hospitals, and bolt-on M&A (Jaypee Healthcare-Noida, Sahara Hospital-Lucknow, Alexis Hospital-Nagpur, and most recently a controlling stake in Kalinga Hospital, Bhubaneswar) to nearly double its bed base toward a stated 10,000-bed target by FY30.

Max Healthcare has compounded revenue at a 27% CAGR and profit at a 60% CAGR over the last five years (consolidated), aided by post-Covid margin normalisation, the ramp-up of acquired hospitals (Nagpur, Lucknow, Noida) and steady ARPOB gains. OPM has expanded from single digits pre-2021 to a stable ~27% band over FY24-26 as the network matured, though the pace of margin expansion has flattened as new, sub-scale hospitals are absorbed into the base.

Free cash flow has compressed sharply in FY26 (₹165 Cr vs ₹500 Cr in FY25) as capex tripled to fund the current wave of brownfield and greenfield bed additions — borrowings rose from ₹1,299 Cr (FY24) to ₹3,478 Cr (FY26). Leverage remains modest relative to EBITDA (net debt/EBITDA under 1.5x), but investors should track whether the capex-heavy phase over FY26-30 pressures FCF and dividend payout (already low at ~13-14% of profits) further before the new capacity starts contributing meaningfully to cash generation.

We project a 10-year explicit free cash flow forecast off the TTM base (Revenue ₹8,712 Cr, EBITDA margin 26.6%), reflecting steep near-term capex tied to the FY26-30 expansion (~₹5,700 Cr planned capex for 3,000+ beds by FY28, plus the Lucknow greenfield and Kalinga integration), before capex intensity normalises as new capacity matures and starts generating cash. We apply a WACC of 12% (reflecting Max’s cost of equity as a levered, expansion-phase healthcare operator) and a terminal growth rate of 5%.

Read with caution: a pure 10-year DCF at a conservative 12% WACC substantially undervalues Max Healthcare relative to its market price — a common outcome for scaled, high-quality hospital franchises where the market prices in a much longer runway of bed-capacity compounding (well beyond a 10-year explicit window), scarcity value of accredited tertiary/quaternary-care real estate in supply-constrained metro markets, and optionality from international patient mix and future M&A consolidation. We therefore treat the DCF as a conservative floor-check rather than the primary valuation anchor, and triangulate it against relative and SOTP valuation below.

Max Healthcare trades at the richest earnings multiple among large listed Indian hospital chains, reflecting its superior margin profile (highest net margin in the peer set) and premium Delhi-NCR/Mumbai asset mix, though Apollo and Narayana screen cheaper on a growth-adjusted basis.

*Aster DM’s P/E is distorted by an exceptional-item-depressed earnings base and is excluded from average calculations below.

Applying a peer-average P/E of ~56x (excluding Aster’s distorted multiple) to Max’s TTM EPS of ₹14.98 implies a fair value near ₹839; a more conservative 35x EV/EBITDA multiple (below Max’s own implied ~45x) on TTM EBITDA of ₹2,318 Cr, net of ~₹3,000 Cr net debt, implies ~₹803/share. Both anchors sit meaningfully below CMP, indicating the current price already embeds a valuation premium to where comparable listed hospital peers trade today.

A replacement-cost approach to Max’s physical bed infrastructure — using an industry rule-of-thumb of ~₹1.5-2 Cr of capital cost per operational bed for tertiary/quaternary-care metro hospitals — values the existing 6,100+ bed network at roughly ₹9,150-12,200 Cr of hard physical assets, well below the company’s consolidated net fixed assets + CWIP of ~₹13,580 Cr (FY26), which already includes land, buildings and equipment for hospitals still ramping up.

The NAV/book-value approach is of limited use for Max Healthcare because the vast majority of the franchise’s economic value sits in intangibles that don’t appear on the balance sheet — accredited brand equity (JCI/NABH), doctor and specialist relationships, referral networks, payor empanelments, and land-scarcity value in supply-constrained metro micro-markets — rather than in the replacement cost of buildings and equipment. We treat NAV purely as a downside floor-reference, not a fair-value anchor.

EPV strips out all future growth assumptions and values the business purely on its current, normalised earnings power in perpetuity: EPV = Normalised NOPAT ÷ WACC.

At ~₹88/share, EPV is a small fraction of CMP — confirming that almost all of Max Healthcare’s ₹1,01,186 Cr market capitalisation is a bet on future earnings growth (bed-capacity expansion, ARPOB gains, margin maturation of new hospitals) rather than a reflection of today’s steady-state earnings power. This is not unusual for an expansion-phase healthcare compounder, but it does mean the stock offers close to zero margin of safety if execution disappoints — any stumble in the FY26-30 capacity build-out has an outsized effect on the growth premium embedded in the price.

We split Max Healthcare into (a) its mature, cash-generative core hospital network, (b) the pipeline of recently acquired/ramping hospitals not yet contributing full-run-rate EBITDA, and (c) the smaller Max@Home and Max Lab diagnostics/homecare businesses.

The SOTP triangulates closely with the relative-valuation range (~₹800-840), reinforcing that CMP embeds roughly a 25-30% premium over what a sum-of-the-parts, peer-benchmarked build suggests today — a premium the market is willing to pay for Abhay Soi’s execution track record and the scarcity of a scaled, investable pure-play hospital compounder in India.

Based on the weighted valuation synthesis (see Verdict), we define three accumulation zones below CMP:

The ₹700-850 Accumulate band aligns with the SOTP and relative-valuation cluster (₹803-839), while sub-₹700 (near the EPV-to-DCF blended floor) would represent a genuine value entry point that has historically only appeared during sharp broad-market corrections or company-specific overhangs (e.g., the FY22 correction), not the base case over the next 12 months absent a de-rating trigger.

An investor buying in the Accumulate zone (₹700-850) for the base-case FY30 outcome would be underwriting roughly a 2.2-2.7x return (including the multiple staying flat-to-modestly-higher), whereas an investor buying at CMP is underwriting the base or bull case simply to earn index-like or modestly better returns — the entry price matters materially to the risk-reward here.

CMP (₹1,038) already sits inside the Reduce zone. Existing long-term holders with a cost base well below CMP may reasonably continue holding for the structural growth story, but fresh capital deployed above ₹1,000 is paying a premium to every valuation method used in this report other than a pure momentum/scarcity-premium framework.

Max Healthcare has laid out one of the most aggressive capacity roadmaps among listed Indian hospital chains: a target of ~10,000 operational beds by FY30, roughly doubling the current 6,100+ bed base, funded by a mix of internal accruals and moderate incremental debt (~₹5,700 Cr planned capex for 3,000+ beds between FY26-28 alone, per brokerage estimates).

Key growth levers: (1) Brownfield tower additions at existing high-ARPOB campuses (400-bed Max Smart Saket tower, 268-bed Nanavati-Max, 160-bed Mohali) that ramp to profitability fastest since they piggyback on established brand, referral base and payor empanelments; (2) Greenfield asset-light “built-to-suit” hospitals (Dwarka, upcoming Mohali/Thane) that reduce upfront capital intensity via O&M-style arrangements; (3) Geographic diversification into non-NCR markets via acquisitions in Lucknow (Sahara Hospital, plus the new 712-bed Shaheed Path greenfield), Nagpur (Alexis Hospital) and now Bhubaneswar (Kalinga Hospital, 58.3% stake, subsequently raised via rights issue) and a signed agreement for a ~450-bed hospital in Pune; (4) continued ARPOB and case-mix improvement via higher international-patient volumes and complex tertiary/quaternary procedures.

Sell-side brokerages (HSIE, Emkay, JPMorgan, UBS) broadly model 18-21% revenue CAGR through FY28 with EBITDA margins holding near 28-29%, and maintain price targets in the ₹1,250-1,300 range — implying the growth thesis is well understood by the market and priced largely off successful execution rather than re-rating surprise.

Promoter holding has stayed rock-steady near 23.7% with zero pledging. The more striking trend is a sustained rotation from foreign to domestic institutional ownership: FII holding has fallen from ~57% (Jun-24) to ~42% (Jun-26), while DII holding has almost doubled from ~15% to ~30% over the same period — driven by growing mutual fund, insurance and pension-fund allocation to India’s largest listed pure-play hospital franchise. Retail/public holding remains modest (~4.5%), and the number of shareholders has nearly doubled to 2.25 lakh over two years, reflecting rising retail interest alongside the stock’s index inclusion (Nifty 50).

Note: figures are parent-AMC/entity-level holdings compiled from third-party ownership trackers and may lag the live quarter or mix scheme-wise data. For the latest scheme-wise mutual fund and FPI-wise shareholding, refer to Max Healthcare’s shareholding pattern filings on the BSE/NSE.